Department of Rheumatology, Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany Background: Magnetic resonance imaging (MRI) of sacroiliac joints has evolved as the most relevant ...

Objectives Familial aggregation of primary Sjögren’s syndrome (pSS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and co-aggregation of these autoimmune diseases (ADs) (also called ...

4 Centro Académico Clínico Egas Moniz, Centro de Investigação em Reumatologia de Aveiro, Aveiro, Portugal 5 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Unidade de ...

Center for Chronic Disease Outcomes Research at the VA Medical Center, Minneapolis, Minnesota, USA Objective: To better understand the impact of gout on functional status, health-related quality of ...

Objective To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2022 update of the ...

1 Department of Neurology, Division of Neuromuscular Disease, Brigham and Women's Hospital and Children's Hospital Informatics Program, Harvard Medical School, Boston, Massachusetts, USA 2 Department ...

The multiple rheumatological faces of PsA (or PsA is more than just poly-arthritis? - Consequences for management in daily practice) ...

SpA: Innovative techniques in spondyloarthritis research – Is there light at the end of the tunnel for our patients?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...

Objectives To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods An ...

Background: Recent EULAR ‘Points to Consider’ provide guidance on management and treatment of Women of Childbearing Age (WoCBA) with chronic rheumatic diseases (CRD: RA, axSpA, PsA). However, it is ...

Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to α4β7 integrin that modulates gut lymphocyte ...